Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Thiosulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 3/20 | 0.35 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
| ▸ | LDHA | P00338 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiosulfuric Acid SCHEMBL4209172 | 0.90 | MEN1 (0.44) | MEN1KMT2AALDH1A1TSHRCA4 | |
| Thiosulfuric Acid SCHEMBL145183 | 0.90 | MEN1 (0.44) | MEN1KMT2AALDH1A1TSHRCA4 | |
| Thiosulfuric Acid SCHEMBL1195014 | 0.90 | ALDH1A1 (0.53) | MEN1KMT2AALDH1A1TSHRCA1 | |
| Thiosulfuric Acid SCHEMBL230064 | 0.90 | MEN1 (0.44) | MEN1KMT2AALDH1A1TSHRCA4 | |
| Thiosulfuric Acid SCHEMBL29211051 | 0.87 | MEN1 (0.50) | MEN1KMT2AALDH1A1TSHRCA1 | |
| Sulfuric Acid SCHEMBL600964 | 0.86 | TSHR (0.69) | MEN1KMT2AALDH1A1TSHRCA4 | |
| Thiosulfuric Acid SCHEMBL262317 | 0.86 | — | — | |
| Thiosulfuric Acid SCHEMBL3422846 | 0.82 | TSHR (0.61) | MEN1KMT2AALDH1A1TSHRCA4 | |
| Thiosulfuric Acid SCHEMBL908689 | 0.82 | — | — | |
| Thiosulfuric Acid SCHEMBL10958542 | 0.82 | TSHR (0.61) | MEN1KMT2AALDH1A1TSHRCA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2024-05-16 | — | — | US | disclosed |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2023-10-10 | — | — | US | disclosed |
| CN-111601798-B | Bisamide sarcomere activating compounds and uses thereof | 美国安进公司 | 2023-08-11 | — | — | CN | disclosed |
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2022-09-08 | — | — | US | disclosed |
| EP-3494960-B1 | STABILIZED COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF USING SAME | HELSINN HEALTHCARE SA (CH) | 2020-11-25 | — | — | EP | disclosed |
| CN-111601798-A | Bisamide sarcomere activating compound and use thereof | 美国安进公司 | 2020-08-28 | — | — | CN | disclosed |
| US-10723720-B2 | Bisamide sarcomere activating compounds and uses therof | AMGEN INC. (US) | 2020-07-28 | — | — | US | disclosed |
| EP-3494960-A1 | STABILIZED COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF USING SAME | Helsinn Healthcare SA (CH) | 2019-06-12 | — | — | EP | disclosed |
| US-20190077793-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2019-03-14 | — | — | US | disclosed |
| WO-2015130890-A9 | SYNTHETIC SALT COMPLEXES FOR IMPROVEMENT OF PLANT GROWTH AND YIELD | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2016-09-29 | — | — | WO | disclosed |
| WO-2001057023-A1 | HETEROCYCLIC AMIDE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2001-08-09 | — | — | WO | disclosed |
| EP-0654031-B1 | STEREOSELECTIVE SYNTHESIS OF NUCLEOSIDE ANALOGUES USING BICYCLIC INTERMEDIATE | IAF BIOCHEM INT (CA) | 1999-12-29 | — | — | EP | disclosed |
| CN-1046720-C | Stereoselective synthesis of nucleoside analogues using bicyclic intermediate | IAF BIOCHEM INT (CA) | 1999-11-24 | — | — | CN | disclosed |
| US-5763606-A | Stereoselective synthesis of nucleoside analogues using bicyclic intermediate | BIOCHEM PHARMA, INC. (CA) | 1998-06-09 | — | — | US | disclosed |
| CN-1110479-A | Stereoselective synthesis of nucleoside analogues using bicyclic intermediate | IAF BIOCHEM INT (CA) | 1995-10-18 | — | — | CN | disclosed |
| EP-0654031-A1 | STEREOSELECTIVE SYNTHESIS OF NUCLEOSIDE ANALOGUES USING BICYCLIC INTERMEDIATE | BIOCHEM PHARMA INC (CA) | 1995-05-24 | — | — | EP | disclosed |
| WO-1994029301-A1 | STEREOSELECTIVE SYNTHESIS OF NUCLEOSIDE ANALOGUES USING BICYCLIC INTERMEDIATE | BIOCHEM PHARMA INC. (CA) | 1994-12-22 | — | — | WO | disclosed |
| US-4233296-A | STEROIDS HAVING PROGESTOMIMETIC PROPERTIES | ROUSSEL UCLAF (FR) | 1980-11-11 | — | — | US | disclosed |
| US-4147695-A | 11β-Substituted-Δ9 -steroids | ROUSSEL UCLAF (FR) | 1979-04-03 | — | — | US | disclosed |
| US-3963772-A | ACRYLIC TELOMERS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1976-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | MEN1 4097/4885KMT2A 1593/4885ALDH1A1 3628/4885 |
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | MEN1 4097/4885KMT2A 1593/4885ALDH1A1 3628/4885 |
| US-20190077793-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | MEN1 4097/4885KMT2A 1593/4885ALDH1A1 3628/4885 |
| US-10723720-B2 | Bisamide sarcomere activating compounds and uses therof | TNNI3, TNNT2, TNNC1 | MEN1 3176/4885KMT2A 2746/4885ALDH1A1 4627/4885 |
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | MEN1 4097/4885KMT2A 1593/4885ALDH1A1 3628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.